Study summary · research use only
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this phase 2 study, the authors evaluated ARA 290, a nonhematopoietic peptide designed from erythropoietin that interacts with the innate repair receptor, in subjects with type 2 diabetes and painful neuropathy. Subjects self-administered ARA 290 (4 mg) or placebo subcutaneously daily for 28 days, then were followed an additional month. The abstract reports no identified safety issues, and that ARA 290 recipients showed improvement in hemoglobin A1c and lipid profiles over the 56-day observation, significant improvement in neuropathic symptoms on the PainDetect questionnaire, and, among subjects with corneal nerve fiber density more than 1 standard deviation from normal, a significant increase in density versus no change with placebo. The authors suggest continued clinical evaluation.
Abstract
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. ARA 290 (4 mg) or placebo were self-administered subcutaneously daily for 28 d and the subjects followed for an additional month without further treatment. No potential safety issues were identified. Subjects receiving ARA 290 exhibited an improvement in hemoglobin A(1c) (Hb A(1c)) and lipid profiles throughout the 56 d observation period. Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.